Sage's depression drug succeeds in mid-stage study, shares soar

loading...


Sage’s depression drug succeeds in mid-stage study, shares soar
(Reuters) – Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal of reducing symptoms in a mid-stage study, sending its shares soaring 52.3 percent in premarket trading.


Source: Health And Fitness

Reply

Pin It on Pinterest

Shares
Share This
loading...